AMO Pharma is developing investigational drugs targeting serious and debilitating rare diseases, including congenital myotonic dystrophy and Phelan-McDermid syndrome, through a robust clinical pipeline. The company focuses on addressing the significant unmet medical needs of patient populations affected by these conditions, where approved therapies are currently lacking.
Funding
$60M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many rare diseases lack effective treatments, leaving patients with serious and debilitating conditions and limited options for care. The development of therapies for these diseases is often challenging due to small patient populations and complex disease mechanisms.
Solution
AMO Pharma is a biopharmaceutical company focused on developing new treatments for rare and debilitating diseases with significant unmet medical needs. The company's pipeline includes clinical-stage investigational drugs targeting neuromuscular and central nervous system symptoms of rare genetic disorders such as congenital myotonic dystrophy and Phelan-McDermid syndrome. AMO Pharma aims to address the challenges of rare disease drug development by combining a deep understanding of the patient experience with expertise in clinical research and product commercialization. The company is committed to advancing promising therapies that can make a positive difference in the lives of patients affected by these conditions.
Target Audience
The primary target audience includes patients affected by rare genetic disorders, their families and caregivers, and healthcare professionals specializing in the treatment of these conditions.
Features
- Clinical-stage investigational drugs targeting rare genetic disorders
- Focus on neuromuscular and CNS symptoms
- Pipeline includes treatments for congenital myotonic dystrophy, Phelan-McDermid syndrome and Rett Syndrome
- Commitment to understanding the patient experience
- Expertise in clinical research and global product commercialization